ReviewHuman vaccines & immunotherapeutics2021
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.
Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026Review
- Allergic Conditions and Their Impact on Pediatric Sleep: A Narrative Review.Journal of pharmacy & bioallied sciences · 2024Review
- Harnessing immunity: Immunomodulatory therapies in COVID-19.World journal of virology · 2024Review
- Review
- Calligraphy of Nanoplasmonic Bioink-Based Multiplex Immunosensor for Precision Immune Monitoring and Modulation.ACS applied materials & interfaces · 2023Article
- Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines.Vaccines · 2023Review
- Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory.Human vaccines & immunotherapeutics · 2022Review
- COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.Human vaccines & immunotherapeutics · 2022Review
- A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19).Cell communication and signaling : CCS · 2022Review
- Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.Immunity, inflammation and disease · 2022Review
- A global picture: therapeutic perspectives for COVID-19.Immunotherapy · 2022Review
- Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma.Molecular therapy oncolytics · 2022Article
- An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19.International immunopharmacology · 2021Review
- Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country.Archives of Razi Institute · 2021Article
- Extracellular Vesicle-Based Therapy for COVID-19: Promises, Challenges and Future Prospects.Biomedicines · 2021Review
- A Catalogus Immune Muris of the mouse immune responses to diverse pathogens.Cell death & disease · 2021Article
- Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Egypt's COVID-19 Recent Happenings and Perspectives: A Mini-Review.Frontiers in public healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc worldwide. Due to the non-availability of any vaccine or drugs against COVID-19, immunotherapies involving convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to enhance immunity are valuable alternative options. Cell-based therapies including natural killer cells, T cells, stem cells along with cytokines and toll-like receptors (TLRs) based therapies are also being exploited potentially against COVID-19. Future research need to strengthen the field of developing effective immunotherapeutics and immunomodulators with a thrust of providing appropriate, affordable, convenient, and cost-effective prophylactic and treatment regimens to combat global COVID-19 crisis that has led to a state of medical emergency enforcing entire countries of the world to devote their research infrastructure and manpower in tackling this pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.